skip to main content
LOTERRE

LOTERRE

Chemical Entities of Biological Interest Ontology (CHEBI)

Choisissez le vocabulaire dans lequel chercher

Langue des données

| español English
Aide à la recherche

Concept information

... > chemical entity > molecular entity > main group molecular entity > p-block molecular entity > chalcogen molecular entity > oxygen molecular entity > organooxygen compound > ether > aromatic ether > linkable vandetanib analogue
... > chemical entity > molecular entity > main group molecular entity > p-block molecular entity > chalcogen molecular entity > organochalcogen compound > organooxygen compound > ether > aromatic ether > linkable vandetanib analogue
... > chemical entity > molecular entity > main group molecular entity > p-block molecular entity > carbon group molecular entity > organic molecular entity > heteroorganic entity > organochalcogen compound > organooxygen compound > ether > aromatic ether > linkable vandetanib analogue
... > chemical entity > molecular entity > polyatomic entity > molecule > cyclic compound > aromatic compound > organic aromatic compound > aromatic ether > linkable vandetanib analogue
... > chemical entity > molecular entity > main group molecular entity > p-block molecular entity > carbon group molecular entity > organic molecular entity > organic molecule > organic cyclic compound > organic aromatic compound > aromatic ether > linkable vandetanib analogue
... > chemical entity > molecular entity > polyatomic entity > molecule > organic molecule > organic cyclic compound > organic aromatic compound > aromatic ether > linkable vandetanib analogue
... > chemical entity > molecular entity > polyatomic entity > molecule > cyclic compound > organic cyclic compound > organic aromatic compound > aromatic ether > linkable vandetanib analogue
... > chemical entity > molecular entity > polyatomic entity > heteroatomic molecular entity > halide > organohalogen compound > organofluorine compound > linkable vandetanib analogue
... > chemical entity > molecular entity > main group molecular entity > p-block molecular entity > halogen molecular entity > halide > organohalogen compound > organofluorine compound > linkable vandetanib analogue
... > chemical entity > molecular entity > main group molecular entity > p-block molecular entity > carbon group molecular entity > organic molecular entity > heteroorganic entity > organohalogen compound > organofluorine compound > linkable vandetanib analogue
... > chemical entity > molecular entity > main group molecular entity > p-block molecular entity > halogen molecular entity > fluorine molecular entity > organofluorine compound > linkable vandetanib analogue
... > chemical entity > molecular entity > main group molecular entity > p-block molecular entity > pnictogen molecular entity > nitrogen molecular entity > organonitrogen compound > organonitrogen heterocyclic compound > quinazolines > linkable vandetanib analogue
... > chemical entity > molecular entity > main group molecular entity > p-block molecular entity > carbon group molecular entity > organic molecular entity > heteroorganic entity > organonitrogen compound > organonitrogen heterocyclic compound > quinazolines > linkable vandetanib analogue
... > chemical entity > molecular entity > polyatomic entity > molecule > cyclic compound > heterocyclic compound > organic heterocyclic compound > organonitrogen heterocyclic compound > quinazolines > linkable vandetanib analogue
... > chemical entity > molecular entity > main group molecular entity > p-block molecular entity > carbon group molecular entity > organic molecular entity > organic molecule > organic cyclic compound > organic heterocyclic compound > organonitrogen heterocyclic compound > quinazolines > linkable vandetanib analogue
... > chemical entity > molecular entity > polyatomic entity > molecule > organic molecule > organic cyclic compound > organic heterocyclic compound > organonitrogen heterocyclic compound > quinazolines > linkable vandetanib analogue
... > chemical entity > molecular entity > polyatomic entity > molecule > cyclic compound > organic cyclic compound > organic heterocyclic compound > organonitrogen heterocyclic compound > quinazolines > linkable vandetanib analogue
... > chemical entity > molecular entity > main group molecular entity > p-block molecular entity > carbon group molecular entity > organic molecular entity > heteroorganic entity > organic heterocyclic compound > organonitrogen heterocyclic compound > quinazolines > linkable vandetanib analogue
... > chemical entity > molecular entity > polyatomic entity > molecule > cyclic compound > heterocyclic compound > organic heterocyclic compound > organic heteropolycyclic compound > organic heterobicyclic compound > quinazolines > linkable vandetanib analogue
... > chemical entity > molecular entity > main group molecular entity > p-block molecular entity > carbon group molecular entity > organic molecular entity > organic molecule > organic cyclic compound > organic heterocyclic compound > organic heteropolycyclic compound > organic heterobicyclic compound > quinazolines > linkable vandetanib analogue
... > chemical entity > molecular entity > polyatomic entity > molecule > organic molecule > organic cyclic compound > organic heterocyclic compound > organic heteropolycyclic compound > organic heterobicyclic compound > quinazolines > linkable vandetanib analogue
... > chemical entity > molecular entity > polyatomic entity > molecule > cyclic compound > organic cyclic compound > organic heterocyclic compound > organic heteropolycyclic compound > organic heterobicyclic compound > quinazolines > linkable vandetanib analogue
... > chemical entity > molecular entity > main group molecular entity > p-block molecular entity > carbon group molecular entity > organic molecular entity > heteroorganic entity > organic heterocyclic compound > organic heteropolycyclic compound > organic heterobicyclic compound > quinazolines > linkable vandetanib analogue
... > chemical entity > molecular entity > polyatomic entity > molecule > cyclic compound > heterocyclic compound > heteropolycyclic compound > organic heteropolycyclic compound > organic heterobicyclic compound > quinazolines > linkable vandetanib analogue
... > chemical entity > molecular entity > polyatomic entity > molecule > cyclic compound > polycyclic compound > heteropolycyclic compound > organic heteropolycyclic compound > organic heterobicyclic compound > quinazolines > linkable vandetanib analogue
... > chemical entity > molecular entity > polyatomic entity > molecule > cyclic compound > heterocyclic compound > heterobicyclic compound > organic heterobicyclic compound > quinazolines > linkable vandetanib analogue
... > chemical entity > molecular entity > polyatomic entity > molecule > cyclic compound > bicyclic compound > heterobicyclic compound > organic heterobicyclic compound > quinazolines > linkable vandetanib analogue
... > chemical entity > molecular entity > polyatomic entity > heteroatomic molecular entity > halide > organohalogen compound > organobromine compound > linkable vandetanib analogue
... > chemical entity > molecular entity > main group molecular entity > p-block molecular entity > halogen molecular entity > halide > organohalogen compound > organobromine compound > linkable vandetanib analogue
... > chemical entity > molecular entity > main group molecular entity > p-block molecular entity > carbon group molecular entity > organic molecular entity > heteroorganic entity > organohalogen compound > organobromine compound > linkable vandetanib analogue
... > chemical entity > molecular entity > main group molecular entity > p-block molecular entity > halogen molecular entity > bromine molecular entity > organobromine compound > linkable vandetanib analogue

Terme préférentiel

linkable vandetanib analogue  

Concept(s) générique(s)

Synonyme(s)

  • 7-(4-aminobutoxy)-N-(4-bromo-2-fluorophenyl)-6-methoxyquinazolin-4-amine

Appartient au groupe

URI

http://data.loterre.fr/ark:/67375/KFP-J3TTD34W-9

Télécharger ce concept:

RDF/XML TURTLE JSON-LD Dernière modif. 25/03/2022